Durlobactam Sodium

CHEMBL4297378 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

299.2 g/mol

LogP

—

Phase

4

A sodium salt form of durlobactam used in combination therapy to treat multidrug-resistant bacterial infections. Like the parent compound, it inhibits bacterial enzymes that would otherwise inactivate the accompanying antibiotic.

Peso Molecular

299,2400 g/mol

TPSA

141,00 Å²

Mecanismo de Ação

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC1=C[C@@H]2CN(C(=O)N2OS(=O)(=O)[O-])[C@@H]1C(N)=O.[Na+]

InChI

InChI=1S/C8H11N3O6S.Na/c1-4-2-5-3-10(6(4)7(9)12)8(13)11(5)17-18(14,15)16;/h2,5-6H,3H2,1H3,(H2,9,12)(H,14,15,16);/q;+1/p-1/t5-,6+;/m1./s1

Molecular Formula

C8H10N3NaO6S

HBD / HBA

1 / 6

Ligações Rotacionáveis

3

Átomos Pesados

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A sodium salt form of durlobactam used in combination therapy to treat multidrug-resistant bacterial infections. Like the parent compound, it inhibits bacterial enzymes that would otherwise inactivate the accompanying antibiotic.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Durlobactam Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297378. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 89851851. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Durlobactam Sodium no PillFYI

Estrutura

Dados Rápidos

Fórmula: C8H10N3NaO6S

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.